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Introduction
Heparin, a negatively charged glycosaminoglycan (3,000–
30,000 Da), is an anticoagulant released by mast cells and 
basophils during the normal clotting process [1]. Heparin 
is widely used for the treatment and prophylaxis of 
thrombo  embolic diseases in medical and surgical 
patients [1]. Heparin-induced thrombocytopenia (HIT) 
is one of the most serious adverse events associated with 
this drug. HIT is an immune-mediated, prothrombotic 
complication that occurs with unfractionated heparin 
(UFH) and to a lesser extent with low-molecular-weight 
heparin (LMWH) [2]. Th   e fundamental paradox of HIT 
results from a platelet-activating immune response trig-
gered by the interaction of heparin with a speciﬁ  c platelet 
protein, platelet factor 4 (PF4) [3].
In this chapter, we review current knowledge about the 
pathophysiology, epidemiology, clinical manifestations, 
and treatment of HIT in the intensive care unit (ICU).
Pathophysiology of HIT
Heparin causes mild platelet aggregation in vivo, 
especially in patients with activated platelets, resulting in 
increased platelet sequestration in the spleen and throm-
bo  cytopenia [1]. Th   rombocytopenia can be triggered via 
non-immune and immune mechanisms. Clinically, two 
types of HIT can be diﬀ  erentiated: HIT type I, a benign 
non-immune condition; and HIT type II, an immune-
mediated syndrome caused by an antibody to the PF4/
heparin complex.
Non-immune HIT, or HIT type I, is a self-limiting 
condition without any major complications that occurs in 
10–30% of patients within 4 days after exposure to 
heparin. Heparin binds to PF4 with high aﬃ   nity  and 
inhibits adenylcyclase. Th   is leads to a decrease in intra-
cellular cyclic adenosine monophosphate (cAMP) levels 
with subsequent reduction in the platelet activation 
threshold and mild platelet aggregation and thrombo-
cyto  penia [4,5]. HIT type I may occur in patients with 
sepsis, burn injuries, and vascular diseases, probably due 
to platelet hyperreactivity in these conditions [4,5]. 
Th  rombocytopenia in HIT type I is usually mild and 
platelet counts rarely decrease below 100,000/μl [6]. 
Heparin administration should be continued and no 
speciﬁ  c therapy is required.
Immune-mediated HIT type II is a disorder initiated by 
an immunological response to heparin exposure and is 
characterized by an absolute or relative thrombocyto-
penia with a paradoxically increased incidence of 
thrombosis (Fig. 1) [1]. Th   e major antigen responsible for 
this syndrome is PF4, which is synthesized by mega-
karyo  cytes and stored in platelet α-granules. Upon 
platelet activation, PF4 is released and binds anionic 
glycosaminoglycans on cell surfaces. Th  e main function 
of PF4 is to inhibit the formation of megakaryocytes and 
angiogenesis, as well as modulating the immune res-
ponse. Considerable amounts of PF4 are released after 
trauma, inﬂ  ammation, surgical trauma, and in neoplasm 
[7]. In HIT type II, heparin infusion displaces PF4 and 
produces structural changes on it, leading to the for-
mation of a PF4/heparin complex. Th   is complex is recog-
nized as a `foreign’ antigen and triggers an immune 
response, which is characterized by the release of IgG 
antibodies that bind to the PF4/heparin complexes with 
subsequent clustering of the platelet Fc-receptors 
(FcχRIIa, FcχRIIIa) resulting in platelet activation. Th  is 
may lead to overt arterial thrombosis, historically, called 
“the white clot syndrome”. Activated platelets can also 
fragment into prothrombotic microparticles and stimu-
late venous thrombosis [5,8]. In addition, HIT antibodies 
may bind to Fc receptors on monocytes which produces 
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under the German Copyright Law.signiﬁ   cant quantities of tissue factor, stimulating 
thrombosis [5,9]. HIT antibodies may promote throm  bo-
sis through platelet adhesion to the vessel wall and for-
ma  tion of platelet-leukocyte aggregates [5,10]. Davidson 
et al. [11] reported elevated levels of von Willebrand 
factor and soluble thrombomodulin in patients with HIT 
type II, suggesting that endothelial cell damage with the 
consecutive loss of its physiologic antithrombotic pro-
perties may contribute to the thrombotic risk.
Heparin molecules bind PF4 in proportion to the length 
of the polysaccharide chain. Th  is explains the higher 
frequency of HIT among patients treated with UFH than 
among those treated with LMWH [12]. Th  e amount of 
anti-PF4/heparin antibodies produced is deter  mined not 
only by the dose and structure of heparin but also by the 
amount of circulating PF4. In some clinical situations, such 
as cardiac surgery, the relatively abundant circulating PF4 
and heparin increase the risk of immunization [7]. PF4 
bound in vivo to cell surface glycos  aminoglycans can be 
immunogenic and could explain why healthy individuals 
may be positive for anti-PF4/heparin antibodies [13]. In 
fact, not all patients who have heparin antibodies develop 
platelet activation and clinically relevant HIT. After 
termination of heparin therapy, the platelet count 
increases within 4 to 14 days [14]. HIT antibodies are 
transient, generally disappearing within 4 months. [15]
HIT type II is the most important clinical entity and 
will be discussed in the following sections. For simplicity, 
we will refer to HIT type II simply as HIT.
Epidemiology
Th  e frequency of HIT in heparin-exposed patients is 
highly variable. Heparin preparation is one inﬂ  uential 
factor with bovine UFH being the most common trigger 
followed by porcine UFH [12]. HIT occurs less commonly 
in patients receiving LMWH. Th  e incidence of HIT is 
1–5% when UFH is used but < 1% with LMWH [12]. 
Females are more likely to develop HIT than males and 
postoperative patients have a higher incidence of HIT 
than have medical ICU patients [16]. Heparin dosage also 
plays an important role. Prophylactic doses of heparin 
increase the risk of antibody formation, whereas clinical 
manifes  tations occur more in patients receiving thera-
peutic doses [16]. Only a small proportion, at most 5% to 
30%, of patients who form HIT-IgG will develop clinical 
HIT [12,17].
Th  e incidence of HIT varies from 0% in pregnant 
women receiving LMWH to 5% in patients undergoing 
Figure 1. Schematic representation of the pathogenesis of HIT (see text for details). From [5] with permission. PF: platelet factor; PMPs: 
platelet microparticles.
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relatively high prevalence of anti-PF4/heparin antibodies 
in patients undergoing cardiac surgery, the incidence of 
HIT in this patient population is about 2.4% [18]. Th  e 
formation of anti-PF4/heparin antibodies varies from 2 to 
5% in cardiology patients, from 15 to 30% in patients 
undergoing orthopedic surgery, and up to 30 to 70% in 
patients undergoing cardiac surgery [19]. Several studies 
have assessed the frequency of HIT in ICU patients [3]; the 
incidence of HIT in ICU patients is generally less than 2%.
Clinical manifestations
HIT is a clinicopathological syndrome with one or more 
clinical events (thrombocytopenia with or without 
thrombosis) temporally related to heparin administration 
and caused by HIT antibodies [20]. Th   e clinical manifes-
tations of HIT are discussed below.
Onset
In patients with HIT, thrombocytopenia typically occurs 
5–10 days after initiation of heparin therapy (typical 
onset HIT) as the immune system requires several days 
to produce suﬃ   cient amounts of anti-PF4/heparin anti-
bodies [21]. Th  rombocytopenia that occurs more than 
10 days after exposure to heparin is probably caused by 
other factors, such as sepsis. In some exceptional cases, 
invasive procedures, such as surgical interventions, may 
promote seroconversion and release of PF4 after long 
periods of exposure to heparin [21].
In the so called `rapid onset’ HIT, thrombocytopenia 
occurs within 24 hours of exposure to heparin, mostly 
due to the presence of anti-PF4/heparin antibodies after 
prior exposure to heparin within the previous 100 days 
[15]. Th  e onset of HIT in these cases is usually accom-
panied by fever, shivering, and skin lesions at the 
injection sites within 30 minutes after heparin adminis-
tration [3]. Some patients also develop acute respiratory 
or cardiac dysfunction, manifested as hypertension, 
tachy  cardia, angina pectoris, or dyspnea. Th  ese  manifes-
tations may suggest pulmonary embolism because of the 
sudden pronounced platelet activation [3,15].
In some patients, HIT may occur after termination of 
heparin therapy. Th  rombotic events or low platelet 
counts may draw attention to the presence of HIT. Th  is 
`delayed onset’ HIT is associated with large numbers of 
anti-PF4/heparin antibodies, which lead to platelet 
activation in the absence of heparin [3]. Th   is entity may 
be clinically relevant in patients who are discharged early 
from the hospital after surgical interventions.
Thrombocytopenia
Th   rombocytopenia is the ﬁ  rst sign of HIT in 85–90% of 
patients who have a decrease in platelet count below 
150,000/μl or a reduction of more than 50% from the 
baseline platelet count [3]. Platelet count usually falls to 
values between 40,000 to 80,000/μl. In only 5–10% of 
cases, does the platelet count reach a nadir below 20,000/μl 
[22], and in such cases other possible causes of thrombo-
cytopenia should be considered.
Th  rombocytopenia is a common laboratory abnor-
mality in critically ill patients. Prospective data from 329 
adult surgical ICU patients during one year showed that 
41.3% had a platelet count less than 150,000/μl at some 
point [23]. Th   e most common etiology of thrombo  cyto-
penia in critical illness is sepsis (around 48%), although 
25% of ICU patients have more than one cause [24]. 
Drug-induced thrombocytopenia must be considered, 
since several medications can cause thrombocytopenia 
and critically ill patients usually receive numerous 
medications [25]. Possible causes of thrombocytopenia 
are shown in Table 1.
Thrombotic complications
HIT is associated with thrombotic complications in 
30–70% of cases. Th   ese may develop without signiﬁ  cant 
thrombocytopenia in 15% of patients [18]. In patients 
with symptomatic deep vein thrombosis (DVT) after 
initiation of heparin therapy, HIT cannot be excluded 
even in the absence of thrombocytopenia. Th  rombotic 
events occur around three days before the onset of 
thrombocytopenia in 40% of HIT patients [26]. Th  e  risk 
of thrombosis correlates, however, to the magnitude of 
relative thrombocytopenia [26].
Th   e most common thrombotic complications in 
patients with HIT include DVT (50%) and pulmonary 
embolism (25%) [27]. Other less common complications 
include myocardial infarction, cardiovascular accidents, 
arterial occlusive lower limb ischemia, sinus vein 
thrombosis, mesenteric venous or arterial occlusion, and 
skin necrosis [28]. Venous thrombosis is 4 to 10 times 
higher than arterial thrombosis [3,27].
Other complications of HIT
Th   e risk of bleeding in patients with HIT is relatively low, 
even at a platelet count of less than 20,000/μl [3]. 
However, bleeding can occur due to thrombocytic dys-
function, such as in patients with uremia. Wester et al. 
[29] compared 20 patients with HIT to 20 ICU patients 
without HIT as a control group. Although patients with 
HIT had a higher incidence of bleeding than the control 
group (85 vs. 35%), bleeding in the HIT patients occurred 
under heparin therapy and was not directly related to 
thrombocytopenia.
In a median of 8 days after the onset of heparin therapy, 
10 to 20% of patients with HIT develop skin lesions in the 
form of erythematous nodules, subcutaneous plaques, or 
necrotic lesions [30]. Skin lesions occur equally after 
treatment with UFH or LMWH [30].
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Th   e `4 T’s’ scoring system is based on thrombocytopenia, 
timing of onset, thrombosis, and absence of other causes 
(Table 2) and allows evaluation of the pretest probability of 
HIT [31]. Patients with low pretest scores (< 4 points) are 
unlikely to be positive for HIT antibodies (0 to 1.6%), 
whereas patients with intermediate (4–5 points) and high 
(> 5 points) scores are more likely to test positive (21.4% to 
100%) [32]. Th   e evaluation of this scoring system showed a 
high negative predictive value in the general population 
and in ICU patients, with low scores being suitable for 
ruling out HIT in most clinical situations [32].
Laboratory diagnosis of HIT
In patients with suspected HIT, diagnosis can be 
established by laboratory testing for the presence of HIT 
antibodies. Two types of assays are available: Functional 
and antigen assays.
Functional assays
Th   ese assays are based on in vitro activation of platelets 
as evidence for the presence of relevant IgG-HIT anti-
bodies [20]. Heparin-induced platelet activation (HIPA) 
and serotonin release assays (SRA) are examples of these 
tests. Washed platelets from healthy volunteers are mixed 
with patient serum and then incubated with low and high 
concentrations of heparin. In the presence of HIT 
antibodies, platelets are activated in low concen  tra  tions of 
heparin. Th   is activation can be detected using radio  active 
serotonin (e.g., SRA) or visually (e.g., HIPA) [19].
Th  e strength of functional assays is their very high 
speciﬁ   city, if the appropriate controls are performed. 
Whether these tests can reach 100% sensitivity depends 
on the `gold standard’ against which they are compared. 
Moreover, functional assays are technically demanding 
(selected platelet donors, washed platelets, internal 
controls, radioactivity), have a high turn-around time, 
and are performed by only a minority of experienced 
laboratories [19].
Antigen assays
Enzyme-linked immunoassays (ELISA) are the tests most 
commonly used to detect HIT antibodies. Th  ese assays 
non-speciﬁ   cally detect IgG, IgA, and IgM antibodies 
against PF4/heparin. Th  e results are analyzed photo-
metri  cally and an optical density higher than 0.4 is 
considered as positive [3]. ELISA is highly sensitive due 
to its ability to detect a broad range of HIT antibodies. 
However, the speciﬁ  city of ELISA is lower compared to 
functional assays [3].
Particle gel immunoassay (PaGIA) is another antigen 
assay that may be used to detect HIT antibodies. Th  e  ID-
heparin/PF4 antibody test (ID-Micro Typing System 
DiaMed®) is a PaGIA, in which a PF4/heparin-coated 
synthetic polymer is used. Th   e agglutination of HIT anti-
bodies in patient serum leads to the formation of bands 
on the gel matrix. Th  e results can be obtained after 
20 minutes. Th   e sensitivity and speciﬁ  city of this test lies 
between the functional tests and the ELISA [33]. PaGIA 
may be used, therefore, as a rapid screening test, pending 
the results of functional assays [33].
Th  e particle immunoﬁ  ltration assay (PIFA) is another 
screening test which involves the use of PF4-coated 
colored polymer particles. Th   is test, however, has 
relatively low performance in terms of speciﬁ  city  and 
sensitivity [34].
Interpretation of the results of laboratory assays
As mentioned above, antigen assays are highly sensitive. 
Th  ese tests can be used, therefore, to exclude the 
Table 1. Diff  erential diagnosis of thrombocytopenia in the ICU
Sepsis and healthcare-associated infections
Drug-induced thrombocytopenia: e.g., GP IIb/IIIa inhibitor, thrombolytic agents, and antibiotics (e.g., vancomycin)
Perioperative fl  uid resuscitation
Disseminated intravascular coagulation (DIC)
Massive transfusion
Intravascular devices: ECMO, IABP, LVAD and pulmonary catheter
Liver disease/hypersplenism
Pulmonary embolism
Immune thrombocytopenias
Diabetic ketoacidosis
Cancer-associated DIC, primary bone marrow disorder
Antiphospholipid syndrome and systemic lupus erythematosis
EDTA-induced pseudothrombocytopenia
ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; LVAD: left ventricular assist device; EDTA: ethylenediaminetetraacetic acid
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conﬁ  rm the diagnosis or reﬂ  ect the risk of thrombotic 
events [35]. Increasing the ELISA optical density thresh-
old from 0.4 to 1 may increase the speciﬁ  city of ELISA 
from 65 to 83% [36]. Th   e combination of functional and 
antigen assays has the highest performance in terms of 
speciﬁ  city and sensitivity [3]. Laboratory assays may help 
to establish the diagnosis of HIT. However, not all PF4/
heparin antibodies are pathologic. Only a subset of 
patients with positive antigen assays has platelet activat-
ing antibodies, of which only a few patients develop 
thrombocytopenia and subsequent thrombosis [37]. 
Hence, this spectrum can be described as an `iceberg 
model’, with clinical HIT as the tip of the iceberg [37]. 
Th  e diagnosis of HIT should be established taking into 
consideration clinical manifestations and laboratory 
evidence [38].
Management of patients with HIT
General measures
If there is a clinical suspicion of HIT, all heparin should 
be stopped, including heparin used to `ﬂ   ush’  intra vascu lar 
catheters, and regional use for dialysis and to coat 
catheters [16,19]. In patients with strongly suspected or 
conﬁ   rmed HIT who do not have active bleeding, 
prophylactic platelet transfusions are not indicated 
because this will lead to subsequent platelet activation 
and increased risk of thrombosis without a net increase 
in platelet count [16].
Alternative anticoagulation
Th  e highest risk of new, progressive, or recurrent 
thrombosis occurs in the ﬁ  rst few days after stopping 
heparin. Alternative therapeutic anticoagulation should 
be initiated based on a high clinical suspicion and not 
delayed while awaiting conﬁ  rmatory laboratory testing or 
because of thrombocytopenia [39]. When treatment was 
delayed pending laboratory conﬁ  rmation of the diagnosis 
within a clinical trial setting, the incidence of new 
thrombosis was approximately tenfold higher than 
during the subsequent period of treatment with a direct 
thrombin inhibitor [40]. Th  erapeutic options include 
direct thrombin inhibitors and factor Xa inhibitors. Oral 
thrombin and factor Xa inhibitors, such as dabigatran, 
rivaroxaban und apixaban, are not yet approved in 
patients with HIT [18]. Th  e choice of alternative anti-
coagulant depends upon availability, associated medical 
conditions, and the preference of the medical staﬀ  .
Heparinoids
Th   ese are direct factor Xa inhibitors, of which danaproid 
is the only available preparation established for use in 
patients with HIT. Danaproid is a mixture of low 
molecular sulphated gylcosaminoglycans: Heparan, 
dermatan, and chondroitin sulfate [18]. It inhibits 
thrombin formation primarily through inhibition of 
factor Xa. Th   e anti-Xa activity of danaparoid has a half-
life of 24 hours. Th   e bioavailability reaches almost 100% 
after intravenous or subcutaneous administration with a 
reliable dose-response curve. Anti-Xa levels (target, 0.5–
0.8 anti-Xa U/ml) may be used to guide danaparoid 
therapy. Monitoring anti-factor Xa activity is important 
in patients with renal dysfunction, as danaparoid is 
partially excreted in the urine [3]. To avoid overdosage, 
monitoring of factor Xa activity is also recommended in 
patients with extremely low or high body weight, life-
threatening thrombosis, bleeding complications, and in 
critically ill patients with marked organ dysfunction or 
comorbidity [3].
Cross reactivity with HIT IgG antibody may occur in 
less than 10% of cases and cannot be predicted by in vitro 
testing prior to onset of therapy [41]. Danaparoid blocks 
HIT antibody-induced platelet aggregation and 
thromboxane B2 production and has been shown to be 
an eﬀ   ective alternative anticoagulant in patients with 
HIT [41]. In some instances, HIT IgG antibody’s cross 
reaction may have clinical consequences. Laboratory 
testing for cross reactivity should be reserved, however, 
Table 2. The 4 T’s score [32]
   Score 
4 T Category  2  1  0
Thrombocytopenia  Platelet count decrease > 50% or   Platelet count decrease 30–50% or  Platelet count decrease < 30% or
  platelet nadir ≥ 20 × 109/L  platelet nadir 10–19 × 109/L  platelet nadir < 10 × 109/L
Time to platelet count   Clear onset between days 5–10 or  Consistent with decrease between  Platelet count decrease < 4 days
decrease*  platelet count decrease ≤ 1 day (prior   days 5–10, but not clear (e.g., missing  without recent exposure
  heparin exposure within 100 days)  platelet counts); onset after day 10 
Thrombosis or other   New thrombosis (confi  rmed); skin  Progressive or recurrent thrombosis;   None
sequelae  necrosis; acute systemic reaction   non-necrotizing (erythematous) skin 
  postintravenous heparin   lesions; suspected thrombosis (not proven) 
Other causes of   None apparent  Possible  Defi  nite
thrombocytopenia
*First day immunizing heparin exposure considered day zero; the day the platelet count begins to decrease is considered the day of onset of thrombocytopenia.
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botic complications during danaparoid therapy or when 
thrombocytopenia persists for more than 4 days after 
onset of therapy. Another anticoagulant should be con-
sidered if the diagnosis is conﬁ   rmed [3,41]. Th  e 
disadvantage of danaparoid therapy is its relatively 
prolonged kinetics in the absence of a speciﬁ  c antidote. 
Overdosage, as manifested by increased anti factor Xa 
activity (> 2 IE/ml) may lead to serious bleeding compli-
cations and increased mortality rates [4]. Adequate 
dosing and monitoring of patients at risk is, therefore, 
mandatory to avoid subsequent complications. Danaparoid 
was withdrawn from the US market in April 2002, but 
remains available for treatment and/or prevention of 
HIT-thrombosis in several other jurisdictions, e.g., 
Canada, Europe, Japan, Australia, and New Zealand.
Direct thrombin inhibitors
Th  ese substances directly inhibit thrombin. Lepirudin, 
argatroban und bivalirudin are available for use in 
patients with HIT.
•  Lepirudin: Lepirudin is a recombinant hirudin (found 
in the saliva of the medicinal leech, Hirudo 
medicinalis) derived from genetically produced 
yeasts. It is approved and available in the USA, 
Canada, Europe, and Australia for treatment of 
thrombosis complicating HIT [42]. Lepirudin binds 
to thrombin and inhibits its prothrombotic activity. 
Th  e activated partial thromboplastin time (aPTT) 
should be targeted at 1.5 to 2.0 times the patient’s 
baseline aPTT or the mean laboratory normal range. 
After intravenous administration, lepirudin reaches a 
peak level within 15 minutes and plasma levels 
maintain a steady state for 1–2 hours [3,43]. To avoid 
overdosage and bleeding complications some authors 
suggest starting intravenous infusion without bolus 
administration, unless fulminant thrombosis is present 
[3]. Dose adjustment is required in patients with renal 
dysfunction, as the drug undergoes renal elimination.
In 30% of patients who are treated with lepirudin, anti-
hirudin IgG antibodies may develop. Th   is was not found 
to be associated with higher risk of thrombosis, bleeding, 
or anaphylactic reactions, thus, lepirudin administration 
should not be discontinued for this reason [3]. Anaphy-
lactic reactions due to lepirudin therapy are rarely ob-
served. Th  e risk of anaphylaxis can be reduced by 
avoiding bolus doses [3]. Th  e risk of bleeding was also 
found to be increased with simultaneous use of 
acetylsalicylic acid [44]. Th  erefore, acetylsalicylic acid 
therapy should be avoided during concomitant therapy 
with direct thrombin inhibitors.
•  Argatroban: Argatroban is a synthetic L-arginine 
derivative. It reversibly inhibits both soluble and clot-
bound thrombin and has a half-life of 50 minutes 
after intravenous administration. Th  e infusion rate 
should be adjusted to target the aPTT at 1.5 to 3 times 
of initial levels. Reduced infusion rates are appropriate 
in patients with heart failure, multiple organ system 
failure, severe anasarca, and during the early post-
cardiac surgery period. In patients with hepatic dys-
function, the half-life increases up to 6 hours, as 
argatroban undergoes hepatobiliary excretion [3]. 
Th  is is particularly relevant in ICU patients because 
of the common occurrence of hepatic perfusion abnor-
malities in the ICU setting [3,45]. Argatroban is 
contraindicated in patients with liver cell failure [3,45].
Th   e advantage of argatroban over LMWH and danparoid 
is the absence of cross reactivity, as argatroban does not 
posses molecular similarity to heparin. In addition, 
antibody formation does not occur, which is an advantage 
compared to lepirudin [46]. Nevertheless, the incidence 
of thromboembolic complications was shown to be 
higher in patients treated with argatroban than in those 
who were treated with lepirudin or danaparoid. Th  is  was 
explained, however, by the shorter duration of argatroban 
therapy compared to lepirudin [40].
•  Bivalirudin: Bivalirudin is a synthetic congener of 
hirudin. It exerts its anticoagulant eﬀ  ect  through 
direct thrombin inhibition. Th   e half-life of bivalirudin 
is 25 minutes after intravenous administration and 
increases to up to 4 hours in patients with renal 
failure undergoing dialysis. Only 20% of the drug is 
excreted in the urine, whereas 80% undergoes 
enzymatic proteolysis [47]. Bivalirudin therapy can be 
monitored by aPTT or the activated clotting time 
(ACT). In the absence of a speciﬁ  c antidote, hemo  ﬁ  l-
tration, hemodialysis, or plasmapharesis may be 
eﬀ   ective therapeutic options [48]. Th   is drug is 
approved in the USA, Canada, Europe, Australia, 
New Zealand, and Latin America for anticoagulation 
during percutaneous transluminal coronary inter-
vention (PCI); in the USA it is also approved for PCI 
with provisional use of glycoprotein IIb/IIIa antago-
nist therapy, and for patients with, or at risk of HIT 
(or HIT with thrombotic complications) undergoing 
PCI; it is also approved in Canada for patients with, or 
at risk of HIT (or HIT with thrombosis syndrome) 
undergoing cardiac surgery. In Germany, bivalirudin 
is not approved in HIT patients but is used `oﬀ  -label’ 
in special situations, such as anticoagulation during 
cardiac surgery in patients with HIT [47].
Th   e anticoagulant eﬀ  ect of bivalirudin is similar to other 
available alternative anticoagulants with a reduced risk of 
bleeding [47]. In patients with renal or hepatic dysfunc-
tion, bivalirudin therapy is advantageous, as it undergoes 
enzymatic proteolysis in addition to renal excretion. 
Cross reactivity with HIT antibodies has not been 
reported [3].
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Fondaparinux is a synthetic, heparin analog, pentasac-
charide anticoagulant. It enhances factor Xa inhibition by 
binding to antithrombin III. Th   e half-life is 18 hours, so 
that it should be administered only once per day [49]. Th  e 
dose response curve is linear. Fondaparinux undergoes 
predominant renal excretion and is, therefore, contra-
indicated in patients with terminal renal failure [50]. Th  e 
anticoagulant eﬀ  ect of fondaparinux is more potent than 
enoxaparin [49]. Th   e risk of bleeding is not increased as 
compared to LMWH [49].
Patients treated with fondaparinux develop anti-PF4/
heparin antibodies with a similar frequency to those 
treated with LMWH [12], but fondaparinux-induced HIT 
appears to be exceptionally rare. Th   is is probably because 
of its short polysaccharide chain of 10–12 saccharides 
and subsequently weak platelet activating potential [50]. 
In the USA, fondaparinux is approved in patients with 
HIT for prophylaxis and treatment of thromboembolic 
diseases. In Germany, this drug is approved for prophy-
laxis after major orthopedic surgery. Th  e anti-factor Xa 
activity of fondaparinux can be useful in patients under 
warfarin therapy who require alternative anticoagulation 
preoperatively. Th   e risk of microvascular thrombosis and 
lower limb gangrene is increased in some patients with 
HIT who receive concomitant therapy with warfarin and 
direct thrombin inhibitors (vide infra) [50]. Fondaparinux 
can be used, therefore, in the transient phase until 
warfarin therapy is withdrawn, to reduce the risk of 
thromboembolic complications in these patients [50]. 
Th  e use of fondaparinux in ICU patients with renal 
insuﬃ   ciency and multiorgan failure is not recommended 
because of the signiﬁ  cant risk of accumulation [3].
Heparin and vitamin K antagonist therapy in patients with 
HIT
To avoid possible bleeding complications with alternative 
anticoagulants in the absence of speciﬁ  c  antidotes, 
patients with known HIT may be treated with heparin for 
short periods, such as those undergoing surgery using a 
heart-lung machine [6]. However, this should only be 
considered when heparin has not been administered 
within the previous 100 days to avoid the occurrence of 
rapid onset HIT. In addition, the presence of anti-HIT 
antibodies should be excluded and use of heparin should 
be avoided during the perioperative period [6].
Vitamin K antagonist therapy is contraindicated in 
patients with HIT because of the increased risk of throm-
bosis in the presence of thrombocytopenia. In these 
patients, vitamin K antagonist therapy may induce lower 
limb venous gangrene or severe skin necrosis. Th  is  occurs 
a few days after the onset of vitamin K antagonist therapy 
[39,51]. Treatment with vitamin K antagonists is asso  cia-
ted with a rapid decrease in protein C concentration, 
which has a short half-life of 6 hours, whereas serum 
levels of procoagulant coagulation factors (Factors II, VII, 
IX, X) remain high during the ﬁ  rst days of therapy. Th  is 
imbalance between pro- and anticoagulant favors a pro-
thrombotic state [4]. Use of vitamin K antagonist therapy 
should be postponed until the platelet count has 
recovered substantially and, thereafter, started at a low 
dose [16]. Alternative anticoagulants should be used 
during thrombocytopenia and should be continued until 
the platelet count has reached a stable plateau and the 
international normalized ratio (INR) has reached the 
intended target range, with a minimal overlap of 5 days 
[14,16]. For patients receiving a vitamin K antagonist at 
the time of diagnosis of HIT, use of vitamin K is 
recommended [16,39,51].
The challenge of diagnosis and treatment of HIT in 
the ICU
Anti-thrombosis prophylaxis is a keystone in the 
management of critically ill patients. In German ICUs, 
99% of patients receive prophylactic anticoagulants, 88% 
receive LMWH and 45% receive UFH during the ICU 
stay [52]. HIT is, therefore, a major concern in ICU 
patients. Nevertheless, thrombocytopenia is a common 
occur  rence in 30–50% of ICU patients, so that diagnosis 
of HIT represents a major challenge [53]. Common 
reasons for thrombocytopenia in these patients include 
sepsis, adverse eﬀ   ects of drugs, transfusion reactions, 
and major surgical procedures [54]. Th   e development of 
thrombotic complications under heparin therapy is, 
there  fore, a better indicator of a diagnosis of HIT than 
uncomplicated thrombocytopenia [3]. Repeated occlu-
sion of hemodialysis ﬁ  lters and necrotic or erythematous 
skin lesions at the site of heparin injections may also be 
an important sign of HIT [3,53]. In this context, the use 
of HIT scores, such as the 4 T’s score, may be helpful in 
establishing the diagnosis (vide supra). In uncomplicated 
cases with a low probability of HIT, heparin 
administration should not be discontinued and further 
laboratory testing is not required. In patients where HIT 
is moderately or strongly suspected, heparin administra-
tion should be stopped pending the results of laboratory 
testing, and alternative anticoagulation should be 
initiated [3]. Even though platelet activation (functional) 
assays are more speciﬁ   c for detecting HIT antibodies 
than antigen tests, neither test is completely speciﬁ  c for 
HIT, which is considered a clinicopathological syndrome 
(vide supra).
Summary and conclusion
HIT is an immune-mediated, prothrombotic complica-
tion that occurs with UFH and to a lesser extent with 
LMWH. HIT is a clinicopathologic syndrome with one or 
more clinical events (thrombocytopenia with or without 
Sakr Critical Care 2011, 15:211 
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Page 7 of 9thrombosis). Th   e diagnosis of HIT can be established by 
laboratory testing for the presence of HIT antibodies. 
Th   e combination of functional and antigen assays has the 
highest performance in terms of speciﬁ  city and sensi-
tivity. Alternative therapeutic anticoagulation should be 
initiated based on high clinical suspicion and not delayed 
while waiting for conﬁ   rmatory laboratory testing or 
because of thrombocytopenia. Th  erapeutic  options 
include direct thrombin inhibitors and factor Xa inhibi-
tors. Th  e choice of alternative anticoagulant depends 
upon availability, associated medical conditions, and 
preferences of the medical staﬀ  . Th   e diagnosis of HIT in 
the ICU is a major challenge as thrombocytopenia is 
prevalent in these patients and generally caused by 
conditions other than HIT. In this context, the use of the 
4 T’s score may be helpful in establishing the diagnosis 
and management of these patients.
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